NICE TA833 - Zanubrutinib for treating Waldenstrom’s macroglobulinaemia. NHSE
commissioned. (Decision date - November 2022)
SSC2569 - Zanubrutinib for treating chronic lymphocytic leukaemia. NHSE commissioned. (Decision date: November 2023)
NICE TA931 - Zanubrutinib for treating chronic lymphocytic leukaemia. NHSE commissioned (Decision date - December 2023)
NICE TA1001 - Zanubrutinib
for treating marginal zone lymphoma after anti-CD20-based treatment. NHSE commissioned (Decision date - October 2024)
DNP:
NICE TA978 (Terminated appraisal) - Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (Decision date - June 2024)
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
